Definitive chemoradiotherapy plus immune checkpoint inhibitors for locally advanced unresectable esophageal squamous cell carcinoma: survival and progression patterns in a propensity-matched cohort.

Median PFS was 18.6 months (95% CI: 14.1–29.5) in the CRT+ICIs group versus 12.1 months (95% CI: 10.1–16.4) in the CRT group, with a nonsignificant trend toward improvement (p = 0.176, Figure 2D ).

also in 5,406 other papers

Using PSM to balance baseline characteristics, we demonstrated that the addition of ICIs to CRT significantly improved OS and showed a trend toward prolonged PFS.

also in 53,322 other papers